Video
Study investigates PSMA-targeted radionuclide therapy in men with mCRPC
Author(s):
“Overall, my take is that even with an intense PSMA-targeted radionuclide regimen, I think the chance of a response… at least by PSA, is higher with stronger baseline PSMA imaging,” says Scott T. Tagawa, MD, MS, FACP.
In this video, Scott T. Tagawa, MD, MS, FACP, discusses the background and findings of the study, “PSMA imaging and outcome following dose-intense PSMA-targeted radionuclide therapy in men with PSMA-unselected, pre-treated, metastatic castration-resistant prostate cancer,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
